Penile Diseases Clinical Trial
Official title:
Efficacy of Penile Traction Therapy Using a Novel Device: A Controlled, Single-blinded, Randomized Trial
This clinical trial is designed to assess the safety, dosing, and preliminary efficacy of a novel penile traction device on correcting deformities relating to Peyronie's disease, a condition which results in penile curvature and length loss. The trial is designed as a randomized, placebo-controlled study with men randomized to receiving no therapy or penile traction therapy 30 minutes once, twice, or three times daily. The study will occur over a 3 month period, after which an open label phase for 3 months will be conducted. Final assessments for adverse effects will also be assessed at 9 months.
Peyronie's disease (PD) is a fibrotic condition of the penis, affecting 1-13% of the US male population. The disease results in penile curvature and significant psychosocial bother. Current preferred therapies for PD include repeated penile injections with bacterial enzymes and surgery. However, these therapies are expensive and in some cases result in permanent reductions in penile length and sensation. Penile traction therapy (PTT) is a relatively newer treatment which has been proposed as a treatment for PD with preliminary data suggesting a potential role. However, currently available PTT devices are primarily designed for penile lengthening and have many significant limitations including a requirement of use for 9 hours daily and significant difficulties in personal application. Given these limitations, a new penile traction device (RestoreX® ) was created and funded through Mayo Ventures and was specifically designed to treat men with PD. The primary objective of the current study is to evaluate safety of the device using various dosing schedules, with secondary endpoints designed to assess efficacy and subjective outcomes. To accomplish the study, a population of men from Mayo Clinic with PD will be enrolled and will be randomized to utilize the device for varying amounts of time. Outcomes will be assessed at 3, 6, and 9 months, and results are to be used with the intent to publish in a scientific journal. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04771442 -
Stem Cell Treatment of Peyronie´s Disease.
|
Phase 1 | |
Completed |
NCT03756688 -
Penile Length Restoration in Men With Diabetes Mellitus, Type II
|
N/A | |
Enrolling by invitation |
NCT05617261 -
Evaluating Patient Tolerability and Success for Penile and Scrotal Urologic Procedures Under Conscious Sedation: A Prospective Study
|
||
Recruiting |
NCT04399057 -
Shear Wave Elastography New Ultrasound Approach for the Erectile Dysfunction
|
||
Completed |
NCT03500419 -
Penile Length Maintenance Post-Prostatectomy
|
N/A | |
Not yet recruiting |
NCT03463239 -
Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora
|
Phase 1 | |
Completed |
NCT04725292 -
Rare Benign Lesion of Peins
|
||
Recruiting |
NCT04821115 -
Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease
|
N/A |